Proteins

# Inhibitors



## ZZL-7

Cat. No.: HY-148417 CAS No.: 99141-91-0 Molecular Formula:  $C_{11}H_{20}N_{2}O_{4}$ Molecular Weight: 244.29

Target: Serotonin Transporter Pathway: **Neuronal Signaling** Storage: 4°C, protect from light

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

**Product** Data Sheet

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 250 mg/mL (1023.37 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.0935 mL	20.4675 mL	40.9350 mL
	5 mM	0.8187 mL	4.0935 mL	8.1870 mL
	10 mM	0.4093 mL	2.0467 mL	4.0935 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) <sup>[1]</sup> .
In Vitro	ZZL-7 (1.0 $\mu$ M; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after

treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time<sup>[1]</sup>. Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment<sup>[1]</sup>.

ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SERT-Cre mice $^{[1]}$	
Dosage:	10 mg/kg	
Administration:	i.p.; once	
Result:	Significantly increased firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice.	

#### **REFERENCES**

[1]. Nan Sun, et al. Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN. Science. 2022 Oct 28;378(6618):390-398.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA